Very smart move by IXC team to get the boundaries negotiated and set early, increasing chances of approval if the study meets its endpoints.
All good news as I see it, with a speedier pathway in EU.
Thumbs up from me.
Ann: Initial FDA and EMA Advice on Presendin Development, page-3
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.712M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 60000 | 7.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.0¢ | 126146 | 1 |
View Market Depth
| Last trade - 07.00am 14/05/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable